Clinical Review

Autoimmune Hemolytic Anemia


 

The autoimmune hemolytic anemias (AIHA) are rare but important hematologic diseases. They can range in severity from mildly symptomatic illness to a rapidly fatal syndrome. The incidence of AIHA is estimated to be between 0.6 and 3 cases per 100,000 persons. AIHA is mediated by antibodies, and in the majority of cases immunglobulin (Ig) G is the mediating antibody. This type of AIHA is referred to as "warm" AIHA because IgG antibodies bind best at body temperature. "Cold" AIHA is mediated by IgM antibodies, which bind maximally at temperatures below 37°C. This manual reviews the most common types of AIHA, with emphasis on diagnosis and treatment.

To read the full article in PDF:

Click here

Recommended Reading

FDA Approves Deferiprone for Transfusional Iron Overload
MDedge Hematology and Oncology
New Data Support Continuing Hydroxyurea for Pediatric Sickle Cell
MDedge Hematology and Oncology
Hematologists, Hospitalists Differ in Care of Sickle Cell Patients
MDedge Hematology and Oncology
Eculizumab gets accelerated approval for aHUS
MDedge Hematology and Oncology
Drug for aHUS effective but expensive
MDedge Hematology and Oncology
FDA approves deferiprone to treat iron overload
MDedge Hematology and Oncology
Newly identified NHP2 biallelic mutation can cause dyskeratosis congenita
MDedge Hematology and Oncology
Despite efficacy, most patients discontinued therapy
MDedge Hematology and Oncology
FDA approves plasma product
MDedge Hematology and Oncology
Team corrects SCD mutation with iPS cells
MDedge Hematology and Oncology